Insider Transactions in Q2 2021 at Invitae Corp (NVTA)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.47%
|
$121,275
$33.02 P/Share
|
|
Jun 21
2021
|
Yafei Wen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Jun 15
2021
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,874
-4.58%
|
$446,220
$30.3 P/Share
|
|
Jun 14
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
21,201
-2.65%
|
$657,231
$31.63 P/Share
|
|
Jun 14
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.58%
|
$307,210
$31.63 P/Share
|
|
Jun 14
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,340
-4.43%
|
$630,540
$31.61 P/Share
|
|
Jun 14
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.93%
|
$307,210
$31.63 P/Share
|
|
Jun 14
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
9,910
-3.86%
|
$307,210
$31.63 P/Share
|
|
May 20
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.46%
|
$102,900
$28.0 P/Share
|
|
May 20
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,116
-7.16%
|
$192,132
$27.62 P/Share
|
|
May 18
2021
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,010
-7.94%
|
$756,270
$27.49 P/Share
|
|
May 18
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,653
-1.28%
|
-
|
|
May 18
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,424
-1.34%
|
$92,448
$27.49 P/Share
|
|
May 06
2021
|
Shelly D Guyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+9.56%
|
-
|
|
Apr 30
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+16.01%
|
-
|
|
Apr 30
2021
|
Kenneth D. Knight Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+11.25%
|
-
|
|
Apr 30
2021
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+14.84%
|
-
|
|
Apr 30
2021
|
Chitra Nayak Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|
|
Apr 30
2021
|
Kimber D Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|
|
Apr 30
2021
|
Geoffrey Crouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+23.44%
|
-
|
|
Apr 30
2021
|
Sean E George Director |
BUY
Grant, award, or other acquisition
|
Direct |
134,200
+14.3%
|
-
|
|
Apr 30
2021
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,700
+31.01%
|
-
|
|
Apr 30
2021
|
Eric Aguiar Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+35.34%
|
-
|
|
Apr 30
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+13.9%
|
-
|
|
Apr 30
2021
|
Christine Marie Gorjanc Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|
|
Apr 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.27%
|
$132,300
$36.55 P/Share
|
|
Apr 14
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
19,893
-3.24%
|
$795,720
$40.26 P/Share
|